List of quality statements

List of quality statements

Statement 1 Pregnant women at increased risk of preterm labour are given information about the potential signs and symptoms.

Statement 2 Women who have had a previous preterm birth or mid-trimester loss and have a cervical length of 25 mm or less measured between 16+0 and 24+0 weeks of pregnancy are offered a choice of either prophylactic vaginal progesterone[1] or prophylactic cervical cerclage.

Statement 3 Women having a planned preterm birth are given information about the risks and potential outcomes.

Statement 4 Women between 26+0 and 33+6 weeks of pregnancy who have intact membranes and are in suspected or diagnosed preterm labour are offered tocolysis.

Statement 5 Women between 24+0 and 33+6 weeks of pregnancy who are in suspected, diagnosed or established preterm labour, are having a planned preterm birth or have preterm prelabour rupture of membranes (P-PROM) are offered maternal corticosteroids.

Statement 6 Women between 24+0 and 29+6 weeks of pregnancy who are in established preterm labour or having a planned preterm birth within 24 hours are offered magnesium sulfate[2].



[1] Although this use is common in UK clinical practice, at the time of publication (August 2019), vaginal progesterone did not have a UK marketing authorisation for this indication. The prescriber should see the summary of product characteristics for the manufacturer's advice on use in pregnancy. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.

[2] Although this use is common in UK clinical practice, at the time of publication (August 2019), magnesium sulfate did not have a UK marketing authorisation for this indication. The prescriber should see the summary of product characteristics for the manufacturer's advice on use in pregnancy. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.